Synergistic effects of anlotinib and DDP on breast cancer: targeting the VEGF/JAK2/STAT3 axis

• Egile Nagusiak: Hongmei Zhang (Egilea), Chunling Liu (Egilea), Ye Jin (Egilea), Zheng Wang (Egilea), Yi Guan (Egilea), Zhenxian Jia (Egilea), Tong Cui (Egilea), Zhi Zhang (Egilea), Xuemei Zhang (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

BackgroundAnlotinib, a highly selective inhibitor of VEGFR2, has demonstrated significant anti-tumor effects in various cancers. However, its potential synergistic effects with DDP (cisplatin) in breast cancer (BRCA) remain to be fully elucidated. This study aims to discover the therapeutic efficacy...